// App-Quantinova.ai

7514 : Results of a randomized, double-blind placebo-controlled phase 3 study evaluating idelalisib in combination with bendamustine and rituximab in patients with relapsed/refractory CLL and adverse prognostic features.

Researchers

Presenter

  • Jacqueline Claudia Barrientos

Principal Investigators

  • Jennifer R. Brown

  • Ehab L. Atallah

  • Steven Coutre

  • Javier De La Serna

  • Herbert Aaron Eradat

  • Charles Michael Farber

  • Ann Janssens

  • Javier Loscertales

  • Christopher Pocock

  • Mazyar Shadman

  • Adeboye H. Adewoye

  • Maria Aiello

  • Lyndah Dreiling

  • Yeonhee Kim

  • Andrew David Zelenetz

  • Stephan Stilgenbauer

Medical Centers

  • Hofstra North Shore-LIJ School of Medicine, Hempstead, NY

  • Dana-Farber Cancer Institute, Boston, MA

  • The Medical College of Wisconsin, Milwaukee, WI

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • UCLA David Geffen School of Medicine, Los Angeles, CA

  • Morristown Memorial Hospital, Carol G. Simon Cancer Center, Morristown, NJ

  • Universitaire Ziekenhuizen Leuven, Leuven, Belgium

  • Hematology Department, Hospital Universitario La Princesa, Madrid, Spain

  • East Kent Hospitals, Canterbury, United Kingdom

  • Seattle Cancer Care Alliance, Seattle, WA

  • Gilead Sciences, Inc., Foster City, CA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • University of Ulm, Ulm, Germany

Locations

  • Spain

  • Germany

  • United Kingdom

  • United States

  • Belgium

Companies

  • Gilead Sciences, Inc

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Bendamustine

  • Idelalisib

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT01569295

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved